Nombre del producto:2-Aminonicotinaldehyde

IUPAC Name:2-aminopyridine-3-carbaldehyde

CAS:7521-41-7
Fórmula molecular:C6H6N2O
Pureza:98%
Número de catálogo:CM103325
Peso molecular:122.13

Unidad de embalaje Stock disponible Precio($) Cantidad
CM103325-25g in stock ǯȀ
CM103325-100g in stock ƄƄư
CM103325-500g in stock ŢưňŔ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :7521-41-7
Fórmula molecular:C6H6N2O
Punto de fusión:-
Código de sonrisas:O=CC1=C(N)N=CC=C1
Densidad:
Número de catálogo:CM103325
Peso molecular:122.13
Punto de ebullición:
Nº Mdl:MFCD01830382
Almacenamiento:Keep in dark place, inert atmosphere, store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Bexotegrast
Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.